Skip to main content

Viking Therapeutics, Inc.

corporate_fare Company Profile

Viking Therapeutics, Inc.

VKTX·NASDAQ·Life Sciences·CIK 0001607678

The company is a clinical-stage biopharmaceutical company focused on developing new therapies for metabolic and endocrine disorders. Its primary product candidate is VK2735, a dual agonist targeting the GLP-1 and GIP receptors. VK2735 is being developed in both oral and subcutaneous forms to potentially treat metabolic disorders like obesity. In January 2022, the company began a Phase 1 clinical trial for VK2735, which included single ascending dose (SAD) and multiple ascending dose (MAD) studies in healthy adults. This trial evaluated the safety, tolerability, and pharmacokinetics of subcutaneously delivered VK2735. The Phase 1 trial was completed in March 2023. Based on these results, in September 2023, the company initiated the VENTURE study, a Phase 2 clinical trial of VK2735 for patients with obesity. This 13-week study enrolled adults who were obese (BMI >= 30 kg/m2) or overweight (BMI >= 27kg/m2) with at least one weight-related co-morbidity. The study's main goal was to measure the percentage change in body weight from baseline to week 13. Patient enrollment for the Phase 2 VENTURE study was completed in October 2023. On February 27, 2024, the company announced that patients receiving weekly doses of VK2735 showed statistically significant reductions in mean body weight after 13 weeks, up to 14.7% from baseline, and up to 13.1% compared to placebo.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for VKTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for VKTX spans 8-K, 424B5, FWP, S-3ASR.

Recent high-impact activity:

  • Q3 Loss Nearly Doubles and Misses Estimates, but Weight-Maintenance Data Lifts Shares 6%
  • Viking Q3 Loss of $1.55/Share Blows Past $1.07 Consensus as Obesity Spend Ramps
  • Viking Q3 Loss Widens to $183.2M as R&D Hits $166.8M; Cash $960M
  • Viking Q3 Loss Widens to $183M as Obesity Phase 3 Spend Ramps; $960M Cash
  • Viking Closes $548M Concurrent Offering After Full Over-Allotment Exercise

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$359.64M
Diluted EPS
-$3.19
Op. Cash Flow
-$278.69M
Operating Income
-$393.34M
Cash & Equivalents
$165.81M
Debt / Equity
0.00×
Shares Outstanding
114.79M sh
Source: 10-K · filed 2026-02-11 · accession 0001193125-26-046876

Short Interest & Short Volume

5.37 days to cover

FINRA reported short interest of 24,163,022 shares in VKTX as of the October 30, 2026 settlement, a 5.4% decrease from the prior period — about 5.4 days to cover at its recent average daily volume. On November 19, 2026, 51.4% of VKTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)24,163,022 shares as of October 30, 2026
Change vs prior period▼ 5.4%
Days to cover5.37 at avg daily volume of 4,502,929
Daily short volume (FINRA facilities)51.4% of 1,500,270 shares on November 19, 2026
5-day average short volume52.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for VKTX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-25.

1 recent capital raiseATM program1 shelf registration

Upsized $500M Concurrent Offering Finalized · Convertible Note Terms Set

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with V →
$25.39 -1.74% today
52-week range · as of 2026-10-28 $23.82 – $43.15
Market cap
$3.23B
Volume
1M (0.2× avg)
3-mo avg 4.2M
Live data · 2026-11-20 16:24 UTC · Market open

show_chartPrice Chart

Loading chart...

feed VKTX - Latest Insights

VKTX
Oct 29, 2026, 10:43 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $27.18
Real-time Price: $25.39 info
Change: -$1.79 (-7%) info
Market Cap: $3.234B info
VKTX
Oct 28, 2026, 5:40 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $24.70
Real-time Price: $25.39 info
Change: +$0.6896 (+3%) info
Market Cap: $3.234B info
VKTX
Oct 28, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $24.38
Real-time Price: $25.39 info
Change: +$1.01 (+4%) info
Market Cap: $3.234B info
VKTX
Oct 28, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $25.41
Real-time Price: $25.39 info
Change: -$0.020 (-0.08%) info
Market Cap: $3.234B info
VKTX
Sep 28, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.28
Real-time Price: $25.39 info
Change: -$7.89 (-24%) info
Market Cap: $3.234B info
VKTX
Sep 28, 2026, 4:30 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $33.16
Real-time Price: $25.39 info
Change: -$7.77 (-23%) info
Market Cap: $3.234B info
VKTX
Sep 24, 2026, 9:05 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $36.98
Real-time Price: $25.39 info
Change: -$11.59 (-31%) info
Market Cap: $3.234B info
VKTX
Sep 24, 2026, 9:04 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $36.98
Real-time Price: $25.39 info
Change: -$11.59 (-31%) info
Market Cap: $3.234B info
VKTX
Sep 24, 2026, 7:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $37.55
Real-time Price: $25.39 info
Change: -$12.16 (-32%) info
Market Cap: $3.234B info
VKTX
Sep 24, 2026, 6:07 AM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $38.11
Real-time Price: $25.39 info
Change: -$12.72 (-33%) info
Market Cap: $3.234B info
VKTX
Sep 23, 2026, 5:13 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $38.48
Real-time Price: $25.39 info
Change: -$13.09 (-34%) info
Market Cap: $3.234B info
VKTX
Sep 23, 2026, 5:13 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $38.48
Real-time Price: $25.39 info
Change: -$13.09 (-34%) info
Market Cap: $3.234B info
VKTX
Sep 23, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $41.43
Real-time Price: $25.39 info
Change: -$16.04 (-39%) info
Market Cap: $3.234B info
VKTX
Sep 23, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $41.68
Real-time Price: $25.39 info
Change: -$16.29 (-39%) info
Market Cap: $3.234B info
VKTX
Sep 22, 2026, 11:42 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $38.13
Real-time Price: $25.39 info
Change: -$12.74 (-33%) info
Market Cap: $3.234B info
VKTX
Sep 22, 2026, 7:09 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $38.31
Real-time Price: $25.39 info
Change: -$12.92 (-34%) info
Market Cap: $3.234B info
VKTX
Sep 22, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.17
Real-time Price: $25.39 info
Change: -$6.78 (-21%) info
Market Cap: $3.234B info
VKTX
Jul 30, 2026, 1:09 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $32.15
Real-time Price: $25.39 info
Change: -$6.76 (-21%) info
Market Cap: $3.234B info
VKTX
Jul 29, 2026, 8:26 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $33.33
Real-time Price: $25.39 info
Change: -$7.94 (-24%) info
Market Cap: $3.234B info
VKTX
Jul 29, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $33.60
Real-time Price: $25.39 info
Change: -$8.21 (-24%) info
Market Cap: $3.234B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets